Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FONTANA phase 1/2 study of AZD5335 alone and in combination in advanced solid tumors
MOH_2023-07-10_012799Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of AZD5335 in ovarian cancer, Non-small cell lung cancer adenocarcinoma (NSCLC), endometrial cancer (EC) and 1 more (13 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability and Recommended phase 2 dose. Started Jun 2022; status: recruiting.
02
Drugs
AZD5335
03
Conditions
ovarian cancerNon-small cell lung cancer adenocarcinoma (NSCLC)endometrial cancer (EC)Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2023-07-10_012799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-10_012799.